Ixekizumab Sustains Plaque Psoriasis Severity Improvement Over 1 Year

Myopenia May Be Common in Rheumatoid Arthritis
March 14, 2019
Crohn’s disease study reveals huge potential for personalised treatment to help more patients
March 14, 2019
Show all

Ixekizumab Sustains Plaque Psoriasis Severity Improvement Over 1 Year

Investigators assessed patients’ scores for body surface area, static Physician Global Assessments, and Dermatology QoL Index at 1 month post-index, and at three-month intervals both pre- and post-index.

A cohort analysis of plaque psoriasis patients treatment in real-world US dermatology referral practices showed that a majority of those treated with ixekizumab achieved clear skin within 3 months.

In new data presented at the American Academy of Dermatology (AAD) 2019 Annual Meeting in Washington, DC, this week, investigators from the US and Canada showed real-world disease severity and quality of life improvements in patients treated with monoclonal antibody ixekizumab. Marketed as Taltz, the Eli Lilly & Company biologic was previously approved for the treatment of plaque psoriasis by the US Food and Drug Administration (FDA) in March 2016.

Ixetizumab binds and blocks interleukin 17 (IL-17) in patients, preventing the pro-inflammatory cytokine from stimulating proliferation and keratinocyte activiation in the skin of patients with plaque psoriasis.

Investigators—led by Craig Leonardi, MD, of Central Dermatology in St. Louis, MO—conducted a cohort analysis of patients treated at a St. Louis-based dermatology practice. The team sought to assess plaque psoriasis severity and quality of life (QoL) in three-month intervals of patients treated with ixekizumab over their first year.

The patient population were 106 adults (median age 47.9 years), 93% Caucasian and 67% male. Another 95% were privately insured. About three-fourths (74%; n= 78) of patients had received previous biologic therapy for their psoriasis—most commonly a tumor necrosis fact (TNF) alpha inhibitor (n= 47), secukinumab (n= 27), and/or ustekinumab (n= 12). Approximately half (52%) had previously received systemic therapy including methotrexate, and another half (51%) received topical treatment.

Investigators assessed the patients’ scores for body surface area (BSA), static Physician Global Assessments (sPGA), and Dermatology QoL Index (DLQI) at 1 month post-index, and at three-month intervals both pre- and post-index.

Read on: Ixekizumab Sustains Plaque Psoriasis Severity Improvement Over 1 Year

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.